Avalon Blogging Develop 
Xconomy
SEPTEMBER 11, 2019
GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.
Xconomy
SEPTEMBER 27, 2016
Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
JANUARY 29, 2020
Agenda topics include Successful Research & Development Models, What It Takes for Commercialization, and Building a Biotech Ecosystem in San Diego. Speakers include Jay Lichter, CEO of COI Pharma and Managing Director at Avalon Ventures; Ciara Kennedy, CEO of Amplyx; and Kim Kamdar, Partner at Domain Associates. $99
Xconomy
AUGUST 17, 2016
and San Diego’s Avalon Ventures. Avelas plans to use the new funding to advance development of AVB-620, the company’s lead diagnostic agent, for use in breast cancer surgeries, CEO Carmine Stengone told me yesterday. Avalon partner Jay Lichter plans to continue serving as Avelas’ chairman, Stengone said.
Xconomy
JULY 20, 2016
First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. It’s a little like what Avalon is doing. We really have a development focus,” Martin told me. “We But it’s structured differently. We outsource everything.
Xconomy
DECEMBER 7, 2018
Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.
Xconomy
NOVEMBER 14, 2018
The San Diego-based company says it wants to use the proceeds to put its lead product candidate, an investigational cancer therapy that’s based on the drug interleukin-2 (IL-2), through dose escalation and expansion trials, and to develop products based on the same compound to treat autoimmune disorders.
Expert insights. Personalized for you.
56 
Let's personalize your content